3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
2
Breast
2
Gynecologic
1
Conditions
Endometrial Neoplasms
22
Ovarian Neoplasms
16
Fallopian Tube Neoplasms
8
Breast Neoplasms
5
Recurrence
4
Carcinoma, Ovarian Epithelial
3
Uterine Neoplasms
2
Uterine Cervical Neoplasms
2
Prostatic Neoplasms
2
Progesterone Resistance
2
Pancreatic Neoplasms
2
Endometrial Hyperplasia
2
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Peritoneal Neoplasms
1
Ovarian Cysts
1
Obesity
1
Neoplasms by Site
1
Neoplasms
1
Low-Grade Serous Ovarian Cancer
1
Low Grade Serous Ovarian Carcinoma
1
Low Grade Serous Ovarian Cancer
1
Leiomyosarcoma
1
Hydatidiform Mole
1
Hereditary Sensory and Autonomic Neuropathies
1
Hereditary Breast and Ovarian Cancer Syndrome
1
Head and Neck Neoplasms
1
Gestational Trophoblastic Disease
1
Interventions
pembrolizumab
35
Paclitaxel
10
Nivolumab
10
Carboplatin
9
atezolizumab
7
Docetaxel
7
Cisplatin
7
Ipilimumab
5
Gemcitabine
5
Cyclophosphamide
5
spartalizumab
4
fludarabine
4
Fluorouracil
4
lenvatinib
3
durvalumab
3
cemiplimab
3
avelumab
3
Vorinostat
3
Trastuzumab
3
Oxaliplatin
3
Leucovorin
3
Immunoglobulin G
3
Fulvestrant
3
Cetuximab
3
Bevacizumab
3
zimberelimab
2
tisotumab vedotin
2
tislelizumab
2
sargramostim
2
aldesleukin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Squamous Cell Carcinoma of Head and Neck
×
Letrozole
×
Gynecologic
×
Clear all
NCT05768139
2026-05-22
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled